NCT01498913已完成不适用
NovoNorm Post Marketing Surveillance Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,841
- 试验地点
- 1
- 主要终点
- HbA1c (glycosylated haemoglobin)
研究概览
简要总结
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
排除标准
- 未提供
研究组 & 干预措施
Repaglinide
干预措施: repaglinide (Drug)
结局指标
主要结局
HbA1c (glycosylated haemoglobin)
2 hours postprandial blood glucose (2-hr PPBG)
Fasting blood glucose (FBG)
Body weight
次要结局
- Adverse events
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2NCT01492153Novo Nordisk A/S1,981
已完成
不适用
Surveillance Study of NovoRapid® for New Drug Re-examinationDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01490112Novo Nordisk A/S1,239
已完成
不适用
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanCongenital Bleeding DisorderHaemophilia ANCT02207218Novo Nordisk A/S40
已完成
不适用
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCongenital Bleeding DisorderGlanzmann's DiseaseNCT01876745Novo Nordisk A/S4
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®DiabetesNCT02821052Novo Nordisk A/S1,355